Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02370875 · ClinicalTrials.gov registry record · NA
rTMS and Botulinum Toxin in Benign Essential Blepharospasm
A NA study of Benign Essential Blepharospasm, sponsored by University of Florida.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT02370875: Completed NA study of Benign Essential Blepharospasm, sponsored by University of Florida.
NCT02370875 is a NA study of Benign Essential Blepharospasm that has completed, run by University of Florida. The registered enrollment target is 12 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02370875, a NA study of Benign Essential Blepharospasm, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Benign essential blepharospasm (BEB) is a functionally disabling focal dystonia. Botulinum neurotoxin (BoNT) therapy is suboptimal in many BEB patients. Repetitious transcranial magnetic stimulation (rTMS) therapy is a promising noninvasive therapy and has shown positive benefits in BEB. rTMS therapy can be easily combined with BoNT injections to enhance the effects of BoNT in BEB.
Primary Outcome
The change in the score of the Jankovic Rating Scale subscore for severity. Rated on a 5-point scale (0-4), where a higher score indicates higher severity of blepharospasm.
Conditions Studied
Interventions
- DEVICE Magstim RapidStim2
- DEVICE Sham Magstim RapidStim2
Study Locations (1)
Florida
- Center for Movement Disorders and Neurorestoration - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-02 |
| Est. Completion | 2017-11 |
| Phase | NA |
What the finished NCT02370875 record still lists
NCT02370875 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Benign Essential Blepharospasm appearing as the primary indexed condition, and to 2 interventions - of which Magstim RapidStim2 is the first listed.
NCT02370875 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT02370875 about?
NCT02370875 is a clinical study titled "rTMS and Botulinum Toxin in Benign Essential Blepharospasm". Benign essential blepharospasm (BEB) is a functionally disabling focal dystonia. Botulinum neurotoxin (BoNT) therapy is suboptimal in many BEB patients. Repetitious transcranial magnetic stimulation (rTMS) therapy is a promising noninvasive therapy and has shown positive benefits in BEB. rTMS therap...
What is the current status of trial NCT02370875?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2015-02. Estimated completion is 2017-11.
What conditions does trial NCT02370875 study?
This clinical trial studies the following conditions: Benign Essential Blepharospasm.
What interventions are being tested in trial NCT02370875?
The interventions under investigation include: Magstim RapidStim2 (DEVICE), Sham Magstim RapidStim2 (DEVICE).
Who is sponsoring clinical trial NCT02370875?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02370875 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Benign Essential Blepharospasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02370875's enrollment target sits among peer trials
12 1913th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia